Keywords: novartis, licenses, antisoma, as1404, deal, worth, up

Novartis licenses Antisoma's AS1404 in deal worth up to $890M

Article | 23 April 2007

Print This

Antisoma has signed an exclusive global licensing agreement with Swiss drug major Novartis for its vascular disrupting agent AS1404, in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in